Clarivate PLC

CLVT

Equity

ISIN JE00BJJN4441 / Valor 47927463

New York Stock Exchange, Inc (2026-06-24)

USD 2.01+4.15%

Clarivate PLC
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Clarivate PLC is a global company that specializes in providing critical insights, analytics, and workflow solutions across various domains of knowledge, research, and innovation. With a workforce of over 11,000 employees worldwide, including industry specialists, consultants, and data scientists, Clarivate caters to the needs of more than 45,000 customers globally. The company's offerings are particularly notable in the biopharmaceutical sector, where it has been a partner to leading companies for over 25 years, assessing R&D and clinical productivity and delivering actionable data and insights. One of its recent innovations is the VeriSIM Life Translational Index™ on Cortellis Drug Discovery Intelligence, which offers predictive compound safety and efficacy insights. As a publicly traded entity on the New York Stock Exchange under the ticker NYSE:CLVT, Clarivate leverages its deep domain expertise to provide subscription and technology-based solutions that support the research and innovation ecosystem. The company's commitment to transforming perspectives and work through trusted intelligence is evident in its comprehensive approach to connecting people and organizations with the information they need to succeed.

Summarized from source with an LLMView SourceSector: Finance

Revenue and organic trends (Q4 & FY 2025)

Q4 2025 revenue: $617.0M vs $663.0M prior year; organic Q4 revenue declined 1.2%. FY 2025 revenue: $2,455.2M (down 4.0% reported), with organic revenue essentially flat (-0.1%).

Recurring revenue mix and ACV (full year)

Organic ACV grew 1.8% in 2025. Recurring revenue mix increased to 88% of total revenue (up 800 bps year‑over‑year), reflecting stronger subscription adoption.

Profitability and non‑GAAP measures

Q4 net income was $3.1M (vs a loss of $191.8M a year earlier); Q4 adjusted net income was $129.7M and adjusted EBITDA was $254.6M. FY adjusted net income was $468.1M and adjusted EBITDA was $1,001.8M (adjusted EBITDA margin ~40.8% for FY).

Cash flow and capital returns

Operating cash flow for FY 2025 was $628.5M and free cash flow was $365.3M. Clarivate repurchased ~$225M of ordinary shares in 2025 (56.0M shares total, including 21.2M in Q4).

Segments and transactional activity

Transactional revenues fell sharply (Q4: $97.1M vs $144.0M prior year), driven by divestitures and lower IP volumes. Subscription revenues showed organic growth (Q4 organic subscription +1.0%).

Balance sheet and debt

Cash and equivalents at year‑end were $329.2M. Total debt outstanding at Dec 31, 2025 was $4,469.9M (down ~$101M year‑over‑year), with additional accelerated repayments completed in Jan 2026.

Strategic review — Life Sciences & Healthcare

Clarivate is pursuing a sale of its Life Sciences & Healthcare segment and has retained Morgan Stanley as advisor; proceeds would be used to focus the portfolio and reduce leverage, though no transaction is assured.

2026 financial outlook (forward‑looking)

Guidance for full‑year 2026: organic ACV +2.0%–3.0%, recurring organic revenue +0.75%–2.25%, revenue $2.30B–$2.42B, adjusted EBITDA $980M–$1.04B (margin 42.0%–43.5%), adjusted diluted EPS $0.70–$0.80, and free cash flow $365M–$435M.

Management commentary

Management cited execution on the Value Creation Plan, investments in proprietary assets and AI capabilities, improved sales execution and margin expansion, and expects continued organic growth and stronger cash conversion in 2026.

Summarized from source with an LLMView Source

Key figures

-51.0%1Y

-77.2%3Y

-92.4%5Y

Performance

65.0%1Y

59.0%3Y

55.1%5Y

Volatility